Bio-Rad Laboratories, Inc. $BIO Stock Position Raised by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,402 shares of the medical research company’s stock after purchasing an additional 178 shares during the period. Envestnet Asset Management Inc. owned 0.38% of Bio-Rad Laboratories worth $24,953,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BIO. Cambridge Investment Research Advisors Inc. increased its holdings in shares of Bio-Rad Laboratories by 25.4% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,033 shares of the medical research company’s stock valued at $252,000 after acquiring an additional 209 shares during the last quarter. New York State Teachers Retirement System increased its holdings in shares of Bio-Rad Laboratories by 1.2% during the 1st quarter. New York State Teachers Retirement System now owns 17,500 shares of the medical research company’s stock valued at $4,262,000 after acquiring an additional 200 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at about $693,000. Principal Financial Group Inc. increased its holdings in shares of Bio-Rad Laboratories by 0.5% during the 1st quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company’s stock valued at $10,800,000 after acquiring an additional 236 shares during the last quarter. Finally, IFM Investors Pty Ltd increased its holdings in shares of Bio-Rad Laboratories by 7.0% during the 1st quarter. IFM Investors Pty Ltd now owns 3,445 shares of the medical research company’s stock valued at $839,000 after acquiring an additional 226 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

BIO has been the topic of a number of analyst reports. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings raised Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 30th. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Wells Fargo & Company raised their target price on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada raised their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $358.50.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $311.13 on Tuesday. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $387.99. The firm has a market capitalization of $8.42 billion, a PE ratio of -12.80 and a beta of 0.97. The business’s 50 day moving average is $298.98 and its 200-day moving average is $265.87. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing the consensus estimate of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The firm had revenue of $653.00 million for the quarter, compared to analyst estimates of $651.30 million. During the same period in the previous year, the business posted $2.01 EPS. Bio-Rad Laboratories’s revenue for the quarter was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.